StockData
Onconetix, Inc. logo

Onconetix, Inc. (ONCO) stock

ONCONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 3/30
$3.21+0.18 (+5.94%)

Close on Nov 13, 2026Market cap $12.68MP/E –Yield –

Onconetix gross margin

Gross margin is gross profit as a percentage of revenue.

Onconetix's gross margin for the twelve months ending Jun 30, 2026 was 80.4%. For fiscal 2025 it was 77.6%, against 41.8% the year before.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202577.6%+35.8
FY2024Dec 31, 202441.8%+1969.7
FY2023Dec 31, 2023-1927.9%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202625.1%−41.1
Q1 FY2026Mar 31, 2026-7.7%−52.8
Q4 FY2025Dec 31, 202581.6%−11.1
Q3 FY2025Sep 30, 202588.6%+62.6
Q2 FY2025Jun 30, 202566.2%+51.9
Q1 FY2025Mar 31, 202545.1%+18.1
Q4 FY2024Dec 31, 202492.7%–
Q3 FY2024Sep 30, 202425.9%–
Q2 FY2024Jun 30, 202414.3%–
Q1 FY2024Mar 31, 202427.0%–

More Onconetix figures

See a number that looks wrong?